Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Bristol's High Profile TYK2 Inhibitor Disappoints In Ulcerative Colitis

07 Oct 2021

• By Jessica Merrill

Time out hands — Bristol's TYK2 inhibitor failed a Phase II study in ulcerative colitis • Source: Alamy

Related Content

Bristol’s Oral TYK2 Inhibitor Beats Amgen’s Otezla In Phase III

04 Nov 2020

Zeposia’s Ulcerative Colitis Approval Provides BMS’s Beachhead Into GI

28 May 2021

FDA Warnings And Restrictions On JAKs Curb Growth Potential Of Big Brands

01 Sep 2021

Related Companies

Bristol Myers Squibb Company

Amgen, Inc.

Pfizer Inc.

AbbVie Inc.

Eli Lilly and Company

Additional Topics

Research & Development Clinical Trials Companies Business Strategies Immune Disorders BioPharmaceutical

More from Immunological

More from Therapy Areas

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.